Essilor : Capital Increase Reserved for Employees
28 November 2014 - 4:23AM
Business Wire
Regulatory News:
Essilor (Paris:EI):
At the Extraordinary Shareholders’ Meeting of May 7, 2014,
Essilor International’s Board of Directors was given a 21-month
authorization to issue shares to members of Essilor employee stock
ownership plans (15th resolution). The maximum number of common
shares authorized for issuance was set at 3,226,452, representing
no more than 1.5% of capital stock.
At its meeting on November 25, 2014, the Board of Directors
decided to use this authorization to issue up to 440,000 common
shares for subscription by members of the Essilor / BBGR / Novacel
Ophtalmique / Novisia / BNL Eurolens / Delamare Sovra and OMI
employee stock ownership plans. The new shares will carry rights as
from January 1st, 2014. They will be offered at a price of €69.73
per share, corresponding to the average of the opening prices
quoted over the last twenty trading days preceding the Board’s
November 25, 2014 decision to issue the shares, less a 20%
discount.
The purpose of this offer is to associate all of the Company’s
employees with its development by allowing them to become
shareholders of the Company. Employees may purchase the shares
through two funds. These funds have been given a specific value
since January 1st, 2014, the start date of the subscription period.
The closing date of the subscription period is December 5, 2014.
The actual number of shares issued will be announced on December
19, 2014 and the Company will then apply for the new shares (par
value: €0.18) to be listed on Euronext Paris.
The Company's capital stock amounts to €38,717,420.76,
represented by 215,096,782 shares.
About Essilor
The world’s leading ophthalmic optics company, Essilor designs,
manufactures and markets a wide range of lenses to correct and
protect eyesight. Its corporate mission is to improve vision to
improve life. To support this mission, the Company allocates more
than €150 million to research and innovation every year, in a
commitment to continuously bring new, more effective products to
market. Essilor’s flagship brands are Varilux®, Crizal®,
Transitions®, Definity®, Xperio®, Optifog™, Foster Grant®, Bolon®
and Costa®. It also develops and markets equipment, instruments and
services for eyecare professionals.Essilor reported consolidated
revenue of over €5 billion in 2013 and employs more than 55,000
people. It distributes its products in some 100 countries with 28
plants, more than 450 prescription laboratories and edging
facilities, as well as several research and development centers
around the world.For more information, please visit www.essilor.com.The Essilor share trades on the
Euronext Paris market and is included in the Euro Stoxx 50 and CAC
40 indices.Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA;
Bloomberg: EI:FP.
EssilorInvestor Relations and Financial
CommunicationsPhone: +33 (0)1 49 77 42 16
Eurogas (CSE:EI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Eurogas (CSE:EI)
Historical Stock Chart
From Dec 2023 to Dec 2024